The Zhitong Finance App learned that Rebang Pharmaceutical-B (09637) rose by more than 6%. As of press release, it had risen 6.02% to HK$28.52, with a turnover of HK$6.4522 million, a volume ratio of 2.26, or 7.06%. The stock was officially included as a constituent stock of Hong Kong Stock Connect and Hang Seng Composite Index on September 7 (Monday), and was actively traded on the first day of trading.
According to Libang Pharmaceutical's voluntary announcement, the company's H shares were included in the Hong Kong Stock Connect Eligible Securities List with effect from September 7, 2026; this inclusion is based on the inclusion of H shares in the Hang Seng Composite Index. Hang Seng Index Limited announced the quarterly review results on August 21. The relevant changes were implemented after the market closed on September 4, and took effect on September 7. The Shenzhen Stock Exchange's announcement on September 7 also confirmed the transfer of 09637 to the Hong Kong Stock Exchange's securities list. The board of directors believes that this move reflects the capital market's recognition of the company's value and long-term development prospects, and will help expand the investor base and enhance the liquidity of H shares trading. As the first innovative pharmaceutical company on the pure kidney disease circuit 18A in the Hong Kong stock market, southbound capital entered the scope of investment after entering the Hong Kong stock market, and liquidity and valuation anchors are expected to improve.
Rebon Pharmaceuticals disclosed its first interim results after listing on August 26. Revenue for the first half of 2026 was RMB104.2 million, up 761.2% year over year, mainly from Mexilla® sales and AP306 license revenue. The loss for the period was RMB 162.6 million, a year-on-year decrease of 22.5%. Among them, the commercial product Mexilla® achieved sales revenue of RMB 24.8 million, an increase of about 105% over the previous year, covering more than 300 hospitals, and the gross margin increased to 47.3% from 43.4% in the first half of 2025.
According to the Huatai Securities Research Report, the company previously reached an exclusive commercial cooperation with Roche on the US and CIA. This product is currently the only product that the company has commercialized. It is expected that Meshin will peak sales of about 1 billion yuan in China in 2034. In addition, the new drug marketing application for the core product AP301 was accepted by the State Drug Administration in August, Global Phase III RESPOND-2 was also completed, and the pipeline continues to be fulfilled.